Table 5.

Fully adjusted analyses of (a) intervention effect on the primary, secondary, and exploratory outcomes, and (b) intervention effect on the primary outcome by baseline compliance.

(a) Intervention effect on outcomes	Adjusted for baseline IFA, gravida, education, age of pregnant woman, gestational age at follow-up
Primary outcome	Odds ratio	Lower 95% CI	Upper 95% CI	p	n	Marginalized difference in proportion	Lower 95% CI	Upper 95% CI	n for marginal effect
Compliance with recommended iron and folic acid tablet (IFA) intake	1.31	0.73	2.35	0.372	265	0.05	−0.06	0.15	277

	Adjusted for baseline outcome (where available), baseline IFA, gravida, education, age of pregnant woman, gestational age at follow-up
Secondary outcomes (counts)	Coefficient (difference)	Lower 95% CI	Upper 95% CI	p	n
Dietary diversity	0.21	−0.14	0.56	0.24	265
Knowledge of iron-rich foods	1.06	0.59	1.52	<0.001	265
ANC visits between baseline and endline	0.04	−0.13	0.21	0.648	265
Binary secondary outcomes	Odds ratio	Lower 95% CI	Upper 95% CI	p	n	Marginalized difference in proportion	Lower 95% CI	Upper 95% CI	n for marginal effect
Consumption of intervention-promoted foods	1.91	1.13	3.22	0.015	265	0.15	0.03	0.26	277
Practicing one or more method to enhance bioavailability including avoiding tea close to meals	4.59	1.26	16.74	0.021	265	0.09	0.01	0.17	277
Exploratory outcomes	Odds ratio	Lower 95% CI	Upper 95% CI	p	n	Marginalized difference in proportion	Lower 95% CI	Upper 95% CI	n for marginal effect
Understanding of why blood tests are taken at antenatal check-ups (among those who had blood tests)	3.20	0.35	29.21	0.302	35	0.18	−0.13	0.50	48
Knowledge of COVID-19 symptoms, precautions and vulnerability	4.25	1.61	11.27	0.004	265	0.11	0.04	0.19	277

(b) Intervention effect on the primary outcome by baseline compliance	Adjusted for baseline IFA, gravida, education, age of pregnant woman, gestational age at follow-up
Disaggregated analyses for women complying and not complying at baseline	Odds ratio	Lower 95% CI	Upper 95% CI	p	n	Marginalized difference in proportion	Lower 95% CI	Upper 95% CI	n for marginal effect	p-value for interaction between IFA compliance at baseline and study arma
Women taking IFA on 12/14 days at baseline	0.93	0.40	2.18	0.871	144	−0.01	−0.14	0.12	149	0.225
Women not taking IFA on 12/14 days at baseline	1.78	0.77	4.12	0.179	121	0.11	−0.05	0.27	128

^aInteraction between IFA compliance at baseline and study arm based on a model adjusted for gravida, education, age of pregnant woman, and gestational age at enrolment.

ANC, antenatal care; COVID-19, coronavirus disease 2019; CI, confidence interval; IFA, iron folic acid.